Testing a new immune cell therapy for aggressive blood cancers in children and adults

Plain-English translation of NCT06514794 on ClinicalTrials.gov ↗ · Source last updated May 2026 · Translation generated July 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This study is testing , a new type of immune cell therapy designed to fight certain aggressive blood cancers called T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma. The treatment works by taking immune cells from a donor, engineering them to recognize and attack cancer cells, and then giving them to the patient. Researchers want to see if this medication can help patients whose cancer has come back or no longer responds to standard treatments.

Many patients with these aggressive blood cancers find that standard treatments stop working, leaving them with very few options. This medication represents a new approach that could offer hope to patients who have run out of other treatments.

Do you qualify?

You likely qualify if…

you have been diagnosed with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has either returned after treatment or is not responding to current treatment
you are at least 6 months old and have adequate organ function
you are in generally good health overall (performance status of 0 or 1)
you have not received any prior anti-CD7 therapy

You likely don't qualify if…

you have previously been treated with any anti-CD7 therapy
you have severe hemolytic anemia (a condition where red blood cells break down too quickly)
you have moderate to severe graft-versus-host disease (a complication from a previous stem cell transplant) requiring ongoing treatment
you currently have untreated infections or other serious medical conditions that would make participation unsafe

What participation looks like

You would receive treatment at a specialized cancer center as part of this multi-site study. First, you would undergo lymphodepletion, a process to prepare your body for the new immune cells. Then you would receive the engineered immune cells through an infusion. You would be closely monitored with regular visits and tests to see how you respond to the treatment and to watch for any side effects.

AI-generated summary from trial data · Jul 15, 2026 · Not medical advice

Trial locations(15 sites)

United States

City of Hope, Duarte, California

Children's Hospital Los Angeles, Los Angeles, California

Colorado Blood Cancer Institute, Denver, Colorado

H. Lee Moffitt Cancer Center and Research Institute Hospital, Tampa, Florida

Washington University Saint Louis, St Louis, Missouri